Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598441 | 0.77 | CYP2D6 (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL808604 | 0.76 | CDK1 (0.47) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6402618 | 0.76 | TLR8 (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8689288 | 0.75 | MEN1 (0.38) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6398172 | 0.74 | CDK1 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL7637855 | 0.72 | MEN1 (0.36) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL899058 | 0.71 | NR5A1 (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL27490484 | 0.71 | MAPK8 (0.32) | NPC1CA12CA1CA2TSHR | |
| SCHEMBL6401579 | 0.70 | TLR8 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6397725 | 0.70 | TLR8 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | claimed |
| US-20120277235-A1 | Compositions For Topical Application Having Androgenic Actions | AVENTIS PHARMA S.A | 2012-11-01 | — | — | US | claimed |
| US-20090093487-A1 | Compositions for topical application having androgenic actions | AVENTIS PHARMA S.A. | 2009-04-09 | — | — | US | claimed |
| EP-1123082-B1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | AVENTIS PHARMA SA (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20050175647-A1 | Compositions for topical application having androgenic actions | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | claimed |
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | US | claimed |
| EP-0879052-B1 | PREPARATIONS STIMULATING NAIL GROWTH | AVENTIS PHARMA GMBH (DE) | 2000-12-20 | — | — | EP | claimed |
| US-6007798-A | TOPICAL VARNISH COMPRISING A VASODILATOR COMPOUND IN WATER INSOLUBLE FILM-FORMING RESIN; FUNGICIDES, PROPHYLAXIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-12-28 | — | — | US | claimed |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20120277235-A1 | Compositions For Topical Application Having Androgenic Actions | AVENTIS PHARMA S.A | 2012-11-01 | — | — | US | disclosed |
| US-20110065763-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA S.A | 2011-03-17 | — | — | US | disclosed |
| US-20090093487-A1 | Compositions for topical application having androgenic actions | AVENTIS PHARMA S.A. | 2009-04-09 | — | — | US | disclosed |
| US-20050175647-A1 | Compositions for topical application having androgenic actions | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | disclosed |
| US-6875438-B2 | Preparations for topical administration of substances having antiandrogenic activity | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-05 | — | — | US | disclosed |
| US-20030229129-A1 | Preparations for topical administration of substances having antiandrogenic activity | AVENTIS PHARMA S.A. (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | US | disclosed |
| US-6007798-A | TOPICAL VARNISH COMPRISING A VASODILATOR COMPOUND IN WATER INSOLUBLE FILM-FORMING RESIN; FUNGICIDES, PROPHYLAXIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | NR5A1, CYP17A1, CYP19A1 | CDK1 3335/4885CCNB1 2584/4885CCNA2 1860/4885 |
| US-20030229129-A1 | Preparations for topical administration of substances having antiandrogenic activity | NR5A1, CYP17A1, HSD17B11 | CDK1 1326/4885CCNB1 456/4885CCNA2 1029/4885 |
| US-20090093487-A1 | Compositions for topical application having androgenic actions | NR5A1, CYP17A1, CYP19A1 | CDK1 3300/4885CCNB1 2611/4885CCNA2 2060/4885 |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | CDK1 3300/4885CCNB1 2611/4885CCNA2 2060/4885 |
| US-20110065763-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | CDK1 3300/4885CCNB1 2611/4885CCNA2 2060/4885 |
| US-20120277235-A1 | Compositions For Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | CDK1 3376/4885CCNB1 2613/4885CCNA2 1853/4885 |
| US-20050175647-A1 | Compositions for topical application having androgenic actions | NR5A1, CYP17A1, CYP19A1 | CDK1 3300/4885CCNB1 2611/4885CCNA2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.